CEO at Lucy Therapeutics
With over 20 years of drug discovery expertise, Amy has led multiple groups bridging big pharma, biotechs and CROs. At Bristol-Myers Squibb, she was part of the teams that discovered and developed Asunaprevir and Daclatasvir, for the treatment of Hepatitis C. Later as Head of Chemistry at EnVivo/FORUM, she led the discovery and development of their PDE10 inhibitor to the clinic. She has cross-functional experience leading teams at several notable Boston biotechs and has served on Executive Leadership Teams at two CROs, SAI Life Sciences and WuXiAppTec. In 2019, Amy founded and secured Seed Round funding for Lucy Therapeutics, a Boston biotech creating a revolutionary mitochondrial drug discovery platform developing treatments for rare neurological and widespread neurodegenerative diseases. She has deep connections in the medicinal chemistry community with long-time service to the ACS MEDI Executive Committee and was the elected Chair of the 2012 Medicinal Chemistry Gordon Research Conference. She is currently a SAB member at Carraway Therapeutics. In her spare time, she plays classical violin professionally in and around the Boston area and has performed with such artists as Yo-Yo Ma, Hillary Hahn, Peter Gabriel, Sarah McLachlan and Smokey Robinson.